Generate QR code
Open Access
Subscription Access
Procalcitonin in new coronavirus infection (COVID-19), complicated by pneumonia, sepsis, in patients with diabetes mellitus
https://doi.org/10.30629/0023-2149-2024-102-7-523-528
Abstract
Objective: to study procalcitonin (PCT) for evaluating the effectiveness of diagnosing pneumonia and sepsis complicating new coronavirus infection in patients with diabetes mellitus and those without it.
Materials and Methods. A total of 65 patients with new coronavirus infection complicated by pneumonia and sepsis were examined, including 35 patients with type 2 diabetes (53.8%). Among the diabetic patients, 20 (30.8%) had complications (diabetic microangiopathies and macroangiopathies). The age of the patients ranged from 42 to 89 years. PCT levels were determined using an automatic immunochemical electro-chemiluminescent analyzer Cobas e 411 (Hitachi High-Technologies Corporation 24-14, 2020). The reference interval for PCT is 0–0.046 ng/ml.
Results. PCT levels in patients with new coronavirus infection complicated by pneumonia and sepsis combined with diabetes (1.7 ± 1.47 ng/ml) did not differ from those in patients without diabetes (3.1 ± 2.96 ng/ml). However, PCT levels in patients with new coronavirus infection complicated by pneumonia and sepsis combined with diabetes and diabetic microangiopathies were higher than those in patients without diabetic microangiopathies.
Conclusion. PCT levels did not differ between patients with new coronavirus infection complicated by pneumonia and sepsis in combination with diabetes and those without diabetes. Thus, PCT serves as a universal marker of the severity of bacterial infection, regardless of the presence of diabetes.
About the Authors
E. A. Titova
Altai State Medical University
Russian Federation
Russian Federation
Elena A. Titova — Doctor of Medical Sciences, Associate Professor, Professor of the Department of Hospital Therapy and Endocrinology
Barnaul
T. A. Lysenko
Regional State Budgetary Healthcare institution «City Hospital No.5, Barnaul»
Russian Federation
Russian Federation
Tatyana A. Lysenko — Head of the endocrinology department
Barnaul
A. G. Koblov
Regional State Budgetary Healthcare institution «City Hospital No.5, Barnaul»
Russian Federation
Russian Federation
Andrey G. Koblov — Deputy Chief Physician for the examination of temporary disability
Barnaul
References
1. Chuchalin AG. Biological markers of respiratory diseases. Terapevticheskiy arkhiv. 2014;(3):4–13. (In Russian)].
2. Khilnani G.C., Tiwari H., Zirpe K.G., Chaudhry D, Govil D., Dixit S. et al. Guidelines for the use of procalcitonin for rational use of antibiotics. Indian Journal of Critical Care Medicine. 2022;(26):77–94. DOI: 10.5005/jp-journals-10071-24326
3. Interim guidelines. Prevention, diagnosis, and treatment of novel coronavirus infection (COVID-19).Versiya 18 (26.10.2023). (In Russian)]. [Electronic resource]. URL: https://static-0.minzdrav.gov.ru/system/attachments/attaches/000/064/610/original/ВМР_COVID-19_V18.pdf. Accessed 16.12.2023.
4. Al-Hussain O.H. Complications and Comorbidities in COVID-19 Patients: A Comparative study. Cureus. 2022;14(8): e28614. DOI: 10.7759/cureus.28614
5. Dedov I.I., Mokry`sheva N.G., Shestakova M.V., Nikonova T.V., Majorov A.Yu., Galstyan G.R.et al. Glycemic control and choice of antihyperglycemic therapy in patients with type 2 diabetes mellitus and COVID-19: consensus decision of the expert council of the Russian Association of Endocrinologists. Saxarny`j diabet. 2022;25(1):27–49. (In Russian)]. DOI: 10.14341/DM12873
6. Algorithms of specialized medical care for patients with diabetes mellitus. Edited by I.I. Dedov, M.V. Shestakova, A.Yu. Majorov. Issue 11. M., 2023. (In Russian)]. DOI: 10.14341/DM13042
7. Nicolau J., Sanchís P., Dotres K., Romano A., Rodríguez I., Masmiquel L. Diabetes might not be a risk factor for worse prognosis among hospitalized patients due to COVID-19 in a Mediterranean area. Nutr. Hosp. 2022;39(3):547–553. DOI: 10.20960/nh.03855
8. Vel'kov V.V. Comprehensive laboratory diagnostics of systemic infections and sepsis: C-reactive protein, procalcitonin, presepsin. 2015:117. (In Rus sian)]. [Electronic resource]. URL: https://diakonlab.ru/files/ComplexLabDiagVVV2014.pdf. Accessed 16.12.2023.
9. Whyte М.В., Vas Р., Heiss Сh., Feherc M.D. The contribution of diabetic micro-angiopathy to adverse outcomes in COVID-19. Diabetes Res. Clin. Pract. 2020;164:108217. DOI: 10.1016/j.diabres.2020.108217
10. Boden I., Bernabeu M.O., Dhillon B., Dorward D.A., MacCormick I., Megaw R., Tochel C. Pre-existing diabetic retinopathy as a prognostic factor for COVID-19 outcomes amongst people with diabetes: A systematic review. Diabetes Res. Clin. Pract. 2022;187:109869. DOI: 10.1016/j.diabres.2022.109869
11. Infante M., Pieri M., Lupisella S., Mohamad А., Bernardini S., Della-Morte D. et al. Admission eGFR predicts in-hospital mortality independently of admission glycemia and C-peptide in patients with type 2 diabetes mellitus and COVID-19. Curr. Med. Res. Opin. 2023;39(4):505–516. DOI: 10.1080/03007995.2023.2177380
12. Mokry'sheva N.G., Shestakova M.V., Vikulova O.K., Elfi mova A.R., Isakov M.A., Gins N.A., Devyatkin A.A., Dedov I.I. Analysis of mortality risks of 337,991 patients with diabetes mellitus who had COVID-19 for the period 2020–2022. All-Russian retrospective study. Vserossijskoe retrospektivnoe issledovanie. Saxarny`j diabet. 2022;25(5):404–417. (In Russian)]. DOI: 10.14341/DM12954
Review
For citations:
Titova E.A., Lysenko T.A., Koblov A.G. Procalcitonin in new coronavirus infection (COVID-19), complicated by pneumonia, sepsis, in patients with diabetes mellitus. Clinical Medicine (Russian Journal). 2024;102(7):523-528. (In Russ.) https://doi.org/10.30629/0023-2149-2024-102-7-523-528
Views:
383
Email this article 